Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Piperacillin + tazobactam + dexamethasone is a combination of two antibiotics and a corticosteroid. Piperacillin is an extended-spectrum penicillin antibiotic that exerts bactericidal activity by inhibiting bacterial cell wall synthesis. Tazobactam is a beta-lactamase inhibitor that prevents the enzymatic breakdown of piperacillin by beta-lactamase-producing bacteria, thereby extending its antibacterial spectrum[1][2][5][6]. Dexamethasone is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressant properties; it acts primarily through glucocorticoid receptor agonism to modulate gene expression and suppress inflammation. This combination may be used in clinical settings where both broad-spectrum antibacterial coverage and anti-inflammatory effects are desired, such as severe infections with significant inflammatory response or off-label in certain complex cases (e.g., severe pneumonia)[4]. The primary indications for piperacillin/tazobactam are moderate to severe bacterial infections including intra-abdominal, skin, gynecological, and respiratory tract infections[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on piperacillin + tazobactam + dexamethasone.